Last reviewed · How we verify
Livmarli Oral Product
Livmarli Oral Product is a Small molecule drug developed by Mirum Pharmaceuticals, Inc.. It is currently FDA-approved. Also known as: Maralixibat.
Livmarli, an oral product developed by Mirum Pharmaceuticals, is currently on the market with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which addresses a significant unmet need in its primary indication. The primary risk to Livmarli is the lack of clear revenue data, which may impact investor confidence and market valuation.
At a glance
| Generic name | Livmarli Oral Product |
|---|---|
| Also known as | Maralixibat |
| Sponsor | Mirum Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Livmarli Oral Product CI brief — competitive landscape report
- Livmarli Oral Product updates RSS · CI watch RSS
- Mirum Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Livmarli Oral Product
What is Livmarli Oral Product?
Who makes Livmarli Oral Product?
Is Livmarli Oral Product also known as anything else?
What development phase is Livmarli Oral Product in?
Related
- Manufacturer: Mirum Pharmaceuticals, Inc. — full pipeline
- Also known as: Maralixibat